79 related articles for article (PubMed ID: 15023570)
1. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial.
Corrigan MH; Gallen CC; Bonura ML; Merchant KM;
Biol Psychiatry; 2004 Mar; 55(5):445-51. PubMed ID: 15023570
[TBL] [Abstract][Full Text] [Related]
2. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
Kramer MS; Last B; Getson A; Reines SA
Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
[TBL] [Abstract][Full Text] [Related]
4. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia.
Redden L; Rendenbach-Mueller B; Abi-Saab WM; Katz DA; Goenjian A; Robieson WZ; Wang Y; Goss SL; Greco N; Saltarelli MD
J Clin Psychopharmacol; 2011 Apr; 31(2):221-5. PubMed ID: 21346607
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
[TBL] [Abstract][Full Text] [Related]
7. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
8. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
9. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia.
Truffinet P; Tamminga CA; Fabre LF; Meltzer HY; Rivière ME; Papillon-Downey C
Am J Psychiatry; 1999 Mar; 156(3):419-25. PubMed ID: 10080558
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
Kane JM; Yang R; Youakim JM
Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
14. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.
Dellva MA; Tran P; Tollefson GD; Wentley AL; Beasley CM
Psychiatr Serv; 1997 Dec; 48(12):1571-7. PubMed ID: 9406266
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
17. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
Meltzer HY; Arvanitis L; Bauer D; Rein W;
Am J Psychiatry; 2004 Jun; 161(6):975-84. PubMed ID: 15169685
[TBL] [Abstract][Full Text] [Related]
18. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
Robb AS; Carson WH; Nyilas M; Ali M; Forbes RA; Iwamoto T; Assunção-Talbott S; Whitehead R; Pikalov A
J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):33-8. PubMed ID: 20166794
[TBL] [Abstract][Full Text] [Related]
19. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison.
Kumra S; Kranzler H; Gerbino-Rosen G; Kester HM; De Thomas C; Kafantaris V; Correll CU; Kane JM
Biol Psychiatry; 2008 Mar; 63(5):524-9. PubMed ID: 17651705
[TBL] [Abstract][Full Text] [Related]
20. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment.
Vayısoğlu S; Anıl Yağcıoğlu AE; Yağcıoğlu S; Karahan S; Karcı O; Gürel SC; Yazıcı MK
Schizophr Res; 2013 Jan; 143(1):207-14. PubMed ID: 23217729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]